NewLimit is a biotechnology company dedicated to extending human healthspan by developing innovative medicines to treat age-related diseases. The company focuses on reprogramming the epigenome to restore the regenerative potential of aged and diseased cells. Utilizing advanced techniques in functional genomics, pooled perturbation screening, and machine learning, NewLimit conducts large-scale experiments to explore the biology of epigenetic aging and disease. The mission is to unlock new therapeutic avenues for improving health in older adults. With a collaborative work environment, employees are encouraged to contribute to both research and decision-making processes, fostering a culture of innovation and execution across diverse scientific teams.